Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cyklx

(Articaine)

PreclinicalSmall molecule

Cyklx is one of 67 small molecule programs targeting Efficacy. It is currently in Preclinical.

2

Indications

16

Total Trials

2

Active Trials

66

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

3

Patents

Pipeline

Status by Indication[3][1]

Indication

EfficacyUnknown status

Blood PressureCompleted

EfficacyPreclinical

Unknown status

Blood PressurePreclinical

Completed

Competition

Competitive Landscape

145 competitors in Efficacy

#DrugCompanyPhaseTrials

Rituxan

Oncovin

Tivicay

Soliris

Rogaine

Paraplatin

Alimta

Lesinurad

EEsperion Therapeutics, Inc.

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Insulin 320

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Chronic Pelvic Pain

NCT07828574

Clinical

Trials by Indication[1]

Anesthesia4 trials

Topical Pharyngeal Anesthesia With Articaine for Gastroscopy

Completed·HHelsinki University Central Hospital·Phase 4·NCT01350050·18 enrolled

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics

Withdrawn·VVirginia Commonwealth University·Phase 2·NCT04105985

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric

Terminated·VVirginia Commonwealth University·Phase 2·NCT03962634·3 enrolled

Show 1 more trial

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General

Withdrawn·VVirginia Commonwealth University·Phase 2·NCT04104789

Pulpitis3 trials

Anesthetic Efficacy of 1,8mL and 3,6mL of Articaine in Inferior Alveolar Nerve Block in Irreversible Pulpitis

Completed·IIsabel Peixoto Tortamano·N/A·NCT02422823·90 enrolled

Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis

Completed·—·N/A·NCT04822415·330 enrolled

4% Articaine and 2% Lidocaine by Intraligamentary Technique in Irreversible Pulpitis

Completed·—·Phase 3·NCT02807298·25 enrolled

Dexmedetomidine2 trials

Articaine Plus Dexmedetomidine in Supraclavicular Block

Recruiting·—·N/A·NCT06423859·66 enrolled

Articaine vs Dexmedetomidine Supplemented Articaine

Completed·—·Phase 1·NCT04171349·50 enrolled

Ambulatory Surgery1 trial

A Comparison of 4% Articaine Versus 0.5%Bupivacaine for Ambulatory Surgery Under Supraclavicular Block

Completed·—·Phase 1·NCT04189198·60 enrolled

Tics1 trial

Comparison of Two Topical Anesthetics: Benzocaine Versus Pliaglis

Completed·UUniversity of Michigan·Phase 4·NCT01951820·64 enrolled

5 more indications

Efficacy1 trial

Anesthetic Efficacy Of 4% ArtpharmaDent Versus 2% Mepecaine-L in Extraction of Lower First Primary Molars

Unknown status·—·N/A·NCT03942991·20 enrolled

Infiltration1 trial

Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction

Completed·—·Phase 4·NCT05443009·76 enrolled

Lidocaine1 trial

Articaine vs Lidocaine for Pediatric Dental Procedures

Withdrawn·—·Phase 4·NCT03318952

Blood Pressure1 trial

Decision Support for Intraoperative Low Blood Pressure

Completed·VVanderbilt University Medical Center·N/A·NCT02726620·22,435 enrolled

Chronic Pelvic Pain1 trial

Efficacy of Pudendal Nerve Block With Articaine and Triamcinolone in Patients With Pudendal Neuropathy: A Prospective Randomized Placebo-Controlled Trial With Blinded Outcome Assessment

Active, not recruiting·IIrkutsk State Medical University·Preclinical·NCT07828574·120 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 15, 2025

CYKLX

NDA NDA218643

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Articaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Articaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Articaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA218643). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Cyklx. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Meitheal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMeitheal

Patent Landscape[5]

Patent Cliff

Mar 27, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12403126Mar 27, 2039

11826347Mar 27, 2039

11096922Mar 27, 2039

Related News